



SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health

Tokyo, April 24, 2012—SBI Pharmaceuticals Co., Ltd., announced that they had obtained Marketing Authorization of their products containing 5-ALA (*1) from The Kingdom of Bahrain Ministry of Health.

SBI Pharmaceuticals signed a Memorandum of Understanding with the Government of The Kingdom of Bahrain for intensive collaboration of R&D and distribution of 5-ALA in Bahrain and other GCC (*2) countries as of April 13.

“While we have obtained Marketing Authorization in Bahrain as a due step of agreed collaboration, we continue to closely work together to get further Marketing Authorization in other GCC countries and establish a joint entity for the project.” said Mr. Kitao, CEO of SBI Pharmaceuticals.

SBI Pharmaceuticals continue to endeavor to support healthy life of people from Japan to the World, by R&D of innovative products containing 5-ALA .

*1 About 5-aminolevulinic acid (5-ALA):

An amino acid created in mitochondria. It is an important substance that serves as protein material related to energy production in the form of hemes and cytochromes, and its productivity is known to decrease with age. 5-ALA is contained in shochu distillation remnants, red wine and food such as radish sprouts. It is also known as a material forming chloroplasts in plants.

*2 About GCC:

An abbreviation for the Gulf Cooperation Council, a regional cooperation organization of Middle East and Arabian Gulf, which Includes Bahrain.

Contact:

SBI Holdings, Inc.: Corporate Communications Dept., inq-all@sbigroup.co.jp Tel: +81 3 6229 0126

SBI Pharmaceuticals Co., Ltd.: Corporate Planning Dept., info_ala@sbigroup.co.jp Tel: +81 3 6229 0095